FDA Official Overrode Reviewers to Clear Replimune's Tudriqev

Asha Das, director of the office of clinical evaluation at the FDA's biologics center (CBER), overruled the agency's own review team to grant accelerated approval to Replimune's melanoma therapy Tudriqev in early August, according to newly released agency documents.

The accelerated approval that put Replimune's melanoma therapy Tudriqev on the U.S. market in early August did not come with the blessing of the reviewers who examined the application. It came over their objection. Newly released documents from the Food and Drug Administration show that Asha Das, director of the office of clinical evaluation at the agency's Center for Biologics Evaluation and Research, overruled the review team's rejection and signed off on the drug herself.

The detail was reported by Endpoints News, drawing on agency documents made public after the decision. Replimune (ticker: REPL) traded at 15.84 a share as of the last trade at 17:43 GMT on Wednesday, up 1.08% on the day from a previous close of 15.67, with a session range of 15.50 to 16.34.

What an override actually means inside CBER

Drug and biologic approvals in the United States are usually described as if the FDA speaks with one voice. In practice, an application moves through a review team \u2014 clinical reviewers, statisticians, product quality and pharmacology staff \u2014 whose written assessments feed into a recommendation. A division or office director then signs the decisional memo. Most of the time that signature ratifies what the reviewers concluded.

When it does not, the disagreement is documented. The signing official has to explain, in writing, why the team's recommendation was set aside. Those memos are what surface in the approval package that the agency posts after a decision, and they are the reason the Replimune sequence is now visible at all. Das holds the office-level role in CBER's clinical evaluation function, which is precisely the level at which such a call gets made and recorded.

Overrides are not, by themselves, improper. They are a built-in feature of a system that gives named officials decision authority rather than delegating it to a vote. But they are uncommon enough that each one becomes a data point in the long-running argument over how much benefit-of-the-doubt the agency should extend to therapies for advanced cancer.

Accelerated approval was the mechanism \u2014 and the pressure point

Tudriqev cleared on the accelerated pathway, which lets the FDA approve a treatment for a serious condition on the strength of a surrogate or intermediate endpoint \u2014 tumor response, for example \u2014 that is considered reasonably likely to predict real clinical benefit, rather than waiting for survival data. The trade-off is a confirmatory obligation: the sponsor has to run a trial that verifies benefit, and the agency retains the ability to withdraw the approval if that trial fails.

That structure is exactly where review teams and signing officials most often part company. A reviewer can accept that a response rate looks real and still argue that a single-arm dataset, or the way responses were measured, is too fragile to support marketing authorization. A decision-maker can look at the same file and conclude that patients with advanced melanoma who have exhausted existing options are better served by access plus a confirmatory requirement than by a delay.

Neither position is obviously wrong. What matters for investors and for physicians is which endpoint the confirmatory trial will read out on, when it reads out, and what the agency has committed to doing if the result is equivocal. Those are the terms buried in the approval documents now in circulation.

Replimune's stock has already been through the round trip

Replimune's shareholders have had a volatile education in how FDA process risk translates into share price. The company's melanoma program went through a regulatory setback before this approval, and the August clearance reversed it. The equity has repriced sharply in both directions along the way \u2014 the kind of single-asset, single-decision profile that makes a mid-cap biotech trade less like a company and more like an option on one signature.

Wednesday's session was quiet by that standard. The shares changed hands at 15.84, with the intraday high of 16.34 sitting roughly 4.3% above Tuesday's close on an illustrative basis, and the low of 15.50 slightly beneath it. For context, the broad market was firmer but unremarkable: the S&P 500 tracker (NYSEARCA: SPY) was at $764.67, up 0.38%, the Nasdaq 100 fund (NASDAQ: QQQ) at $708.08, up 0.06%, and the Dow tracker (NYSEARCA: DIA) at $529.76, up 0.38%, all as of the same 17:43 GMT print.

The muted reaction is itself informative. Disclosure that an approval was granted over reviewer objection does not change the label, the launch, or the reimbursement path today. It changes the perceived durability of the approval \u2014 a risk that sits years out, at the confirmatory readout, not in this quarter's revenue line.

Why the documents matter beyond one drug

Approval packages that reveal internal dissent tend to have a long half-life. They get cited in congressional oversight letters, in Government Accountability Office reviews of the accelerated pathway, and by payers building utilization-management criteria. A commercial insurer's pharmacy committee reading that the FDA's own review team recommended against approval has a ready-made argument for tighter prior authorization, even where the label is broad.

They also matter to the next sponsor in line. Biotech management teams calibrate their regulatory strategy on precedent: which office signed, on what evidence, and how much internal disagreement the agency was willing to absorb. An override that holds up encourages companies to push single-arm datasets forward. An override that later collapses when a confirmatory trial misses does the opposite, and hardens reviewer resistance for years afterward.

What to watch from here

Several things are worth tracking, none of which are settled by the documents themselves.

• The confirmatory commitment. The specific trial, its endpoint and its due date determine when the approval is genuinely tested.
• Whether the FDA comments publicly. Agency leadership sometimes addresses high-profile overrides directly; silence is also a signal.
• Payer coverage language. Restrictive criteria that lean on the review team's objections would blunt the commercial value of the approval.
• Launch metrics. Prescriber uptake in advanced melanoma will show whether oncologists weigh the internal disagreement at all.
• Congressional attention. The accelerated pathway remains a standing target for oversight, and documented overrides are the material such inquiries are built from.

For now, Tudriqev is approved, on the market, and carrying a confirmatory obligation. The documents do not undo any of that. What they do is put a name and a paper trail on a decision that could easily have gone the other way \u2014 and give both the drug's supporters and its skeptics something concrete to point at.

Key facts

• Stock: REPL \u2014 15.84, +1.08%, as of 17:43 GMT, Sept. 2, 2026
• Decision maker: Asha Das, director, CBER office of clinical evaluation
• Approval type: Accelerated approval, granted early August
• Drug: Tudriqev, a Replimune melanoma treatment

Frequently asked questions

What did the FDA documents reveal about Tudriqev's approval?

Newly released agency documents show that Asha Das, director of the office of clinical evaluation at the FDA's Center for Biologics Evaluation and Research, overruled the agency's own review team, which had recommended rejection, and granted accelerated approval to Replimune's melanoma treatment Tudriqev in early August 2026.

Is it legal for an FDA official to overrule a review team?

Yes. Approval authority rests with named signing officials, not with a vote of the review team. When a director departs from the reviewers' recommendation, the reasoning must be documented in the decisional memo, and that memo typically becomes public in the approval package the agency posts afterward.

What is accelerated approval?

It is a pathway that allows the FDA to approve a treatment for a serious condition based on a surrogate or intermediate endpoint, such as tumor response, that is reasonably likely to predict clinical benefit. The sponsor must then run a confirmatory trial, and the agency can withdraw the approval if benefit is not verified.

How did Replimune shares trade on the news?

Replimune (REPL) changed hands at 15.84 as of the last trade at 17:43 GMT on Sept. 2, 2026, up 1.08% from a previous close of 15.67, within a session range of 15.50 to 16.34. The move was modest against a broadly firmer market that day.

Does the override put the approval at risk?

Not immediately. Tudriqev remains approved and on the market. The practical risk sits at the confirmatory trial, where a failure or an ambiguous result could trigger withdrawal proceedings. Documented internal dissent can also give payers grounds to impose tighter coverage restrictions in the meantime.

Why does this matter to other biotech companies?

Sponsors calibrate regulatory strategy on precedent. An approval granted over reviewer objection signals how much weight FDA leadership will give to single-arm or surrogate-endpoint data in advanced cancer. How this one holds up over time will influence both company filing decisions and reviewer posture on future applications.

Sources

• CBER official overruled review team's rejection of new Replimune melanoma drug — Endpoints News

Photo: Quang Vuong · Pexels Licence — source